Medimmune, Abpro Enter Collaborative Agreement
News Nov 29, 2016
MedImmune and Abpro announced they have entered into a collaborative agreement to advance the development of a preclinical, novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF). The agreement is structured as a spin out, benefiting from both companies’ scientific expertise and AbPro’s day-to-day leadership as it oversees the new company, AbMed.
Several potential therapeutic areas will be explored where inhibition of the Ang2 and VEGF pathways with this unique bispecific antibody may provide clinical benefit.
Scientists at MedImmune leveraged the company’s significant experience with bispecific antibody development, engineering a novel bispecific antibody that demonstrated potent activity in animal models, which may be useful in targeting disease indications with high unmet need. AbPro will bring strong scientific, technical and clinical expertise to the new company moving forward, and its core technology platform, DiversImmune, will be used to further refine the antibody.
“This agreement arises out of MedImmune’s culture of entrepreneurship and innovation — both in science and in business,” said Jane Osbourn, Vice President of R&D, MedImmune. “We believe partners like Abpro can help us maximize our extensive pre-clinical portfolio to advance therapies for patients.”
Ian Chan, CEO and Co-founder of Abpro said: “This collaboration further validates our platform’s ability to develop therapeutic antibodies against traditionally difficult targets, with compelling prospects for potential clinical utility.”
Story from MedImmune. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Antigen Study Shows Promise for a Respiratory Syncytial Virus VaccineNews
Medical researchers have been trying to develop a vaccine for respiratory syncytial virus (RSV) for more than 50 years, without success. New findings however, point to a promising route for designing an effective vaccine. Researchers determined the atomic structure of RSV G (major viral surface protein) and identified two sites on it that are targeted by protective antibodies effective against a broad range of RSV strains.READ MORE
The Enemy Within: Gut Bacteria Drive Autoimmune DiseaseNews
Bacteria found in the small intestines of mice and humans can travel to other organs and trigger an autoimmune response, according to a new study. The researchers also found that the autoimmune reaction can be suppressed with an antibiotic or vaccine designed to target the bacteria.READ MORE
Empowering Women in Technology Key to Boosting UK EconomyNews
A new report launched at London Stock Exchange for International Women’s Day, reveals the critical role women play in driving economic growth across the UK, with detailed research on 1,279 women-led companies showing a total contribution of £25.9 billion in revenue to the UK economy.READ MORE
Comments | 0 ADD COMMENT
International Conference on Neuroimmunology, Neurological disorders and Neurogenetics
Sep 26 - Sep 27, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018